

Highlights of This Issue 2315

SPECIAL FEATURES


CCR Translations

- 2317** Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine
Soumaya Karaki, Helene Pere, Cecile Badoual, and Eric Tartour
See related article, p. 2342
- 2320** Therapeutic Guide for mTOuRing through the Braided Kidney Cancer Genomic River
Martin H. Voss and James J. Hsieh
See related article, p. 2445

CCR Perspectives in Regulatory Science and Policy

- 2323** The Role of Neoadjuvant Trials in Drug Development for Solid Tumors
Samuel A. Funt and Paul B. Chapman

Perspectives

- 2329** Dual Faces of IFN γ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
 Masaki Mandai, Junzo Hamanishi, Kaoru Abiko, Noriomi Matsumura, Tsukasa Baba, and Ikuo Konishi

SPECIAL REPORT

- 2335** The Impact of Alternative Payment Models on Oncology Innovation and Patient Care
Amy M. Miller, Gilbert S. Omenn, and Marcia A. Kean

CANCER THERAPY: CLINICAL

- 2342** Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
Mariëtte I.E. van Poelgeest, Marij J.P. Welters, Renee Vermeij, Linda F.M. Stynenbosch, Nikki M. Loof, Dorien M.A. Berends-van der Meer, Margriet J.G. Löwik, Ineke L.E. Hamming, Edith M.G. van Esch, Bart W.J. Hellebrekers, Marc van Beurden, Henk W. Schreuder, Marjolein J. Kagie, J. Baptist M.Z. Trimbos, Lorraine M. Fathers, Toos Daemen, Harry Hollema, A. Rob P.M. Valentijn, Jaap Oostendorp, J. Hanneke N.G. Oude Elberink, Gertjan J. Fleuren, Tjalling Bosse, Gemma G. Kenter, Theo Stijnen, Hans W. Nijman, Cornelis J.M. Melief, and Sjoerd H. van der Burg
See related commentary, p. 2317
- 2351** A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer
Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian J. Druker, Thomas O'Hare, Marc Ladanyi, and Monika A. Davare
- 2359** Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
Candida Vitale, Lorenzo Falchi, Elisa ten Hacken, Hui Gao, Hila Shaim, Katrien Van Roosbroeck, George Calin, Susan O'Brien, Stefan Faderl, Xuemei Wang, William G. Wierda, Katayoun Rezvani, James M. Reuben, Jan A. Burger, Michael J. Keating, and Alessandra Ferrajoli
- 2368** A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Alex A. Adjei, Donald A. Richards, Anthony El-Khoueiry, Fadi Braiteh, Carlos H.R. Becerra, Joe J. Stephenson Jr, Aram F. Hezel, Morris Sherman, Lawrence Garbo, Diane P. Leffingwell, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li-Tain Yeh, Sonny Gunawan, David M. Wilson, Kimberly J. Manhard, Prabhu Rajagopalan, Heiko Krissel, and Neil J. Clendeninn

Table of Contents

PERSONALIZED MEDICINE AND IMAGING

- 2377** Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
Ines P. Silva, Amel Salhi, Keith M. Giles, Matjaz Vogelsang, Sung W. Han, Naima Ismaili, Kevin P. Lui, Eric M. Robinson, Melissa A. Wilson, Richard L. Shapiro, Anna Pavlick, Judy Zhong, Tomas Kirchhoff, and Iman Osman

- 2386** Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich, Jonathan W. Goldman, Jong-Mu Sun, Elaina Mann, Lecia V. Sequist, Krzysztof Konopa, Wei Wen, Philipp Angenendt, Leora Horn, David Spigel, Jean-Charles Soria, Benjamin Solomon, D. Ross Camidge, Shirish Gadgil, Cloud Paweletz, Lin Wu, Sean Chien, Patrick O'Donnell, Shannon Matheny, Darrin Despain, Lindsey Rolfe, Mitch Raponi, Andrew R. Allen, Keunchil Park, and Heather Wakelee

- 2396** SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer
Erica Hlavin Bell, Arup R. Chakraborty, Xiaokui Mo, Ziyang Liu, Konstantin Shilo, Simon Kirste, Petra Stegmaier, Maureen McNulty, Niki Karachaliou, Rafael Rosell, Gerold Bepler, David P. Carbone, and Arnab Chakravarti

- 2405** Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease
Marie Klintman, Richard Buus, Maggie Chon U. Cheang, Amna Sheri, Ian E. Smith, and Mitch Dowsett

- 2417** An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Nicholas P. Tobin, Kristian Wennmalm, Linda S. Lindström, Theodoros Foukakis, Liqun He, Guillem Genové, Arne Östman, Göran Landberg, Christer Betsholtz, and Jonas Bergh

- 2427** The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study
Hans Christian Rolff, Ib Jarle Christensen, Ben Vainer, Lars Bo Svendsen, Rikke Løvendahl Eefsen, Michael Wilhelmsen, Ida Katrine Lund, Gunilla Høyer-Hansen, Hans Jørgen Nielsen, and Martin Illemann, For the Danish Collaborative Research Group on Colorectal Cancer

- 2435** Fc- γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer
Geoffrey Liu, Dongsheng Tu, Marcia Lewis, Dangxiao Cheng, Leslie A. Sullivan, Zhuo Chen, Eric Morgen, John Simes, Timothy J. Price, Niall C. Tebbutt, Jeremy D. Shapiro, G. Mark Jeffery, J. Daniel Mellor, Thomas Mikeska, Shakeel Virk, Lois E. Shepherd, Derek J. Jonker, Christopher J. O'Callaghan, John R. Zalberg, Christos S. Karapetis, and Alexander Dobrovic

- 2445** Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
David J. Kwiatkowski, Toni K. Choueiri, André P. Fay, Brian I. Rini, Aaron R. Thorner, Guillermo de Velasco, Magdalena E. Tyburczy, Lana Hamieh, Laurence Albiges, Neeraj Agarwal, Thai H. Ho, Jiayi Song, Jean-Christophe Pignon, Pablo M. Barrios, M. Dror Michaelson, Eliezer M. Van Allen, Katherine M. Krajewski, Camillo Porta, Sumanta Kumar Pal, Joaquim Bellmunt, David F. McDermott, Daniel Y.C. Heng, Kathryn P. Gray, and Sabina Signoretti
See related commentary, p. 2320

CANCER THERAPY: PRECLINICAL

- 2453** Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy
Valeria Gonzalez-Nicolini, Sylvia Herter, Sabine Lang, Inja Waldhauer, Marina Bacac, Michaela Roemmele, Esther Bommer, Olivier Freytag, Erwin van Puijbroek, Pablo Umaña, and Christian A. Gerdes

- 2462** CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia
Feng-Ting Liu, Li Jia, Ping Wang, Timothy Farren, Hong Li, Xishan Hao, and Samir G. Agrawal

- 2470** Targeting MYCN-Driven Transcription by BET-Bromodomain Inhibition
Anton Henssen, Kristina Althoff, Andrea Odersky, Anneleen Beckers, Richard Koche, Frank Speleman, Simon Schäfers, Emma Bell, Maike Nortmeyer, Frank Westermann, Katleen De Preter, Alexandra Florin, Lukas Heukamp, Annika Spruessel, Kathy Astrahanseff, Sven Lindner, Natalie Sadowski, Alexander Schramm, Lucile Astorgues-Xerri, Maria E. Riveiro, Angelika Eggert, Esteban Cvitkovic, and Johannes H. Schulte

Table of Contents

- 2482** A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma
Regina T. Martuscello, Vinata Vedam-Mai, David J. McCarthy, Michael E. Schmoll, Musa A. Jundi, Christopher D. Louviere, Benjamin G. Griffith, Colby L. Skinner, Oleg Suslov, Loic P. Deleyrolle, and Brent A. Reynolds

- 2496** SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway



Claudia C.S. Chini, Jair M. Espindola-Netto, Gourish Mondal, Anatlilde M. Gonzalez Guerrero, Veronica Nin, Carlos Escande, Mauro Sola-Penna, Jin-San Zhang, Daniel D. Billadeau, and Eduardo N. Chini

- 2508** The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase

Tatiana Erazo, Mar Lorente, Anna López-Plana, Pau Muñoz-Guardiola, Patricia Fernández-Nogueira, José A. García-Martínez, Paloma Bragado, Gemma Fuster, María Salazar, Jordi Espadaler, Javier Hernández-Losa, Jose Ramon Bayasas, Marc Cortal, Laura Vidal, Pedro Gascón, Mariana Gómez-Ferreria, José Alfón, Guillermo Velasco, Carles Domènech, and Jose M. Lizcano

- 2520** Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression

Benjamin Ory, Marc Baud'huin, Franck Verrecchia, Bénédicte Brounais-Le Royer, Thibaut Quillard, Jérôme Amiaud, Séverine Battaglia, Dominique Heymann, Françoise Redini, and François Lamoureux

- 2534** The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects

Jeyran Shahbazi, Pei Y. Liu, Bernard Atmadibrata, James E. Bradner, Glenn M. Marshall, Richard B. Lock, and Tao Liu

- 2545** Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells

Wei Zhang, Bin Yi, Chao Wang, Dongquan Chen, Sejong Bae, Shi Wei, Rong-Jun Guo, Changming Lu, Lisa L.H. Nguyen, Wei-Hsiung Yang, James W. Lillard, Xingyi Zhang, Lizhong Wang, and Runhua Liu

- 2555** Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression

Chiun Hsu, Liang-In Lin, Yu-Che Cheng, Zi-Rui Feng, Yu-Yun Shao, Ann-Lii Cheng, and Da-Liang Ou

BIOLOGY OF HUMAN TUMORS

- 2565** Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer

Matthew R. Farren, Thomas A. Mace, Susan Geyer, Sameh Mikhail, Christina Wu, Kristen Ciombor, Sanaa Tahiri, Daniel Ahn, Anne M. Noonan, Miguel Villalona-Calero, Tanios Bekaii-Saab, and Gregory B. Lesinski

- 2575** A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases

Vinod P. Balachandran, Arshi Arora, Mithat Gönen, Hiromichi Ito, Simon Turcotte, Jinru Shia, Agnes Viale, Nikol Snoeren, Sander R. van Hooff, Inne H.M. Borel Rinkes, René Adam, T. Peter Kingham, Peter J. Allen, Ronald P. DeMatteo, William R. Jarnagin, and Michael I. D'Angelica

- 2583** Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer



Wolfgang J. Janni, Brigitte Rack, Leon W.M.M. Terstappen, Jean-Yves Pierga, Florin-Andrei Taran, Tanja Fehm, Carolyn Hall, Marco R. de Groot, François-Clement Bidard, Thomas W.P. Friedl, Peter A. Fasching, Sara Y. Brucker, Klaus Pantel, and Anthony Lucci

LETTERS TO THE EDITOR

- 2594** The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Letter

Leticia G. Leon, Niccola Funel, Godefridus J. Peters, Amir Avan, Fabio Vistoli, Ugo Boggi, and Elisa Giovannetti

- 2595** The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy—Response

Francesca Vena, John A. Hartley, and Daniel Hochhauser

CORRECTION

- 2596** Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

AC icon indicates Author Choice


CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover figure, which has been truncated, illustrates the results of unsupervised hierarchical clustering of gene-expression profiles of 86 out of the original 126 breast tumors for which there was residual disease after neoadjuvant chemotherapy. The clustering identified patients with an enhanced risk of recurrence who, predominantly, had disease that was ER-negative and/or highly proliferative (as evidenced by high Ki67). The first column from the left indicates the presence of recurrence; the second column, ER-positivity; the third column, HER2-positivity; and the last column, residual Ki67, ranging from 0 to 100%. For details, see the complete figure in the article by Klintman and colleagues on page 2405 of this issue.



Clinical Cancer Research

22 (10)

Clin Cancer Res 2016;22:2315-2596.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/22/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/22/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.